Vanda Pharmaceuticals Inc (Nasdaq: VNDA), a global biopharmaceutical company, announced its financial results for the full year ended 31 December 2020 on Wednesday.
The company reported income before taxes at USD31.7m in 2020 compared to USD29m in 2019.
The firm posted net income of USD23.3m in 2020, compared to net income of USD115.6m in 2019. It reported diluted net income per share of USD0.42 in 2020 compared to diluted net income per share of USD2.11 in 2019.
'I am very proud of the significant accomplishments we realised during this challenging year,' said Mihael H Polymeropoulos, Vanda's MD, president and CEO.
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025
Sanofi finalizes acquisition of Blueprint Medicines to expand rare disease and immunology portfolio
Perrigo to divest Dermacosmetics business for up to EUR327m
CVS Health declares quarterly dividend USD0.665 per share
Lilly declares dividend of USD1.50 for Q3
Bavarian Nordic sells US Priority Review Voucher for USD160m